Home Vaccines Tags

View the Latest: Vaccines

Filter

List Grid

101 - 110 of 331 Results

  • KFF COVID-19 Vaccine Monitor: September 2022

    Poll Finding

    Our latest Vaccine Monitor survey finds that half of the public has heard either “a lot” or “some” about the newly-available bivalent COVID-19 boosters, and a third (32%) say they’ve already gotten it or intend to do so “as soon as possible.” It also updates parents’ vaccine intentions for their children, including those under 5.

  • Half of Public Has Heard Little or Nothing About the New COVID-19 Booster Aimed at Omicron; Many Don’t Know If the CDC Recommends That They Get the New Booster

    News Release

    Nearly 1 in 5 Parents of Children Under 5 Say Their Child Has Gotten a Vaccine, up from 7% in July, Though Half Say They Will “Definitely Not” Get Their Child Vaccinated Less than a month after the Food and Drug Administration authorized new COVID-19 booster shots that target both the omicron and original strains,…

  • Medicaid and the Inflation Reduction Act of 2022

    Policy Watch

    The recent passage of the Inflation Reduction Act of 2022 (IRA) includes a number of climate, tax, and health care provisions and prescription drug reforms. This policy watch explores the potential impacts of the Inflation Reduction Act on overall Medicaid spending as well as implications for Medicaid beneficiaries.

  • Analysis: There is Significant Variation in State and Local Eligibility Criteria for Monkeypox Vaccines, and Vaccine Information is not Always Accessible

    News Release

    According to a new KFF analysis assessing monkeypox (MPX) vaccine eligibility across the United States, people who are exposed or presumed exposed to MPX are generally eligible to get a vaccine across the country. However, eligibility varies across the United States for certain workers, including laboratory staff and others who might be at increased risk.

  • Assessing Monkeypox (MPX) Vaccine Eligibility Across the United States

    Issue Brief

    This analysis examines jurisdictional approaches to eligibility for monkeypox (MPX) vaccine. Overall, almost all jurisdictions have, at minimum, adopted the current approach laid out by the CDC. However, there is substantial variation in how eligibility is defined. Additionally, several jurisdictions lack clear criteria or information on who is eligible or where to get vaccinated. This may impact on who gets vaccinated, lead to geographic disparities, and raises potentially equity challenges.

  • Monkeypox (MPX) Cases and Vaccinations by Race/Ethnicity

    Issue Brief

    A small number of states, as well as some local jurisdictions, are reporting race/ethnicity data on MPX cases and vaccinations and these data show a disproportionate impact of MPX cases on Black and Hispanic people. The data available to date on vaccinations also suggest that Black and Hispanic people are receiving smaller shares of vaccinations despite accounting for larger shares of cases.

  • Monkeypox Vaccine Roll-out in the U.S. – Are Jurisdictions Requesting All Their Doses?

    Policy Watch

    This analysis examines monkeypox vaccine allocations and jurisdictional requests. It explores jurisdictional request rate (the number of vaccine does requested as a share of the jurisdiction’s allocation from HHS) for JYNNEOS, the preferred vaccine. Overall, while most jurisdictions have requested at least their full supply, some are well below that mark, raising questions about how quickly their at-risk populations can get protected.

  • Update: The Number of People Not Up to Date on Vaccination in Counties with Elevated COVID-19 Community Levels is Growing

    Issue Brief

    This post provides updated estimates the number of people who are not up-to-date on COVID-19 vaccination living in counties designated by the CDC as being "high" or "medium" COVID-19 community levels. These are areas of elevated risk, with relatively high levels of new COVID-19 cases and strained hospital capacity. This analysis finds that the number of those not up to date on COVID-19 vaccination, and the most at risk for severe illness, living in areas of elevated risk has grown since early June 2022.